Ikarian Capital, LLC Crispr Therapeutics Ag Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $1.54 Million - $2.89 Million	40,000 Added 130.95%	70,546 $4.42 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $1.39 Million - $1.8 Million	30,546 New	30,546 $1.39 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $1.96 Million - $3.11 Million	-27,968 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $10.1 Million - $14.4 Million	-91,743 Reduced 76.64%	27,968 $3.13 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $10.6 Million - $16.9 Million	104,627 Added 693.63%	119,711 $19.4 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $1.67 Million - $3.17 Million	15,084 New	15,084 $1.84 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.